Abstract
The sigma-1 receptor is a 26 kDa endoplasmic reticulum resident membrane protein that has been shown to have chaperone activity in addition to its promiscuous binding to pharmacological agents. Ligand binding domain(s) of the sigma-1 receptor have been identified using the E. coli expressed and purified receptor protein and novel radioiodinated azido photoaffinity probes followed by proteolytic and chemical cleavage strategies. The outcome of these experiments indicates that the sigma-1 receptor ligand binding regions are formed primarily by juxtaposition of its second and third hydrophobic domains, regions where the protein shares considerable homology with the fungal enzyme, sterol isomerase that is essential for the biosynthesis of ergosterol. Data indicate that these hydrophobic steroid binding domain like (SBDL) regions on the sigma-1 receptor are likely to interact selectively with N-alkyl amines such as the endogenous sphingolipids and with synthetic N-alkylamines and N-aralkylamines derivatives. A proposed model for the sigma-1 receptor is presented.
Keywords: Sigma-1 receptor, photoaffinity labeling, ligand binding region, shingosine, N-alkylamines, chaperone, yeast sterol isomerase, mutagenesis, oligodendrocytes, sphingosine
Current Pharmaceutical Design
Title: The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines
Volume: 18 Issue: 7
Author(s): Arnold E. Ruoho, Uyen B. Chu, Subramaniam Ramachandran, Dominique Fontanilla, Timur Mavlyutov and Abdol R. Hajipour
Affiliation:
Keywords: Sigma-1 receptor, photoaffinity labeling, ligand binding region, shingosine, N-alkylamines, chaperone, yeast sterol isomerase, mutagenesis, oligodendrocytes, sphingosine
Abstract: The sigma-1 receptor is a 26 kDa endoplasmic reticulum resident membrane protein that has been shown to have chaperone activity in addition to its promiscuous binding to pharmacological agents. Ligand binding domain(s) of the sigma-1 receptor have been identified using the E. coli expressed and purified receptor protein and novel radioiodinated azido photoaffinity probes followed by proteolytic and chemical cleavage strategies. The outcome of these experiments indicates that the sigma-1 receptor ligand binding regions are formed primarily by juxtaposition of its second and third hydrophobic domains, regions where the protein shares considerable homology with the fungal enzyme, sterol isomerase that is essential for the biosynthesis of ergosterol. Data indicate that these hydrophobic steroid binding domain like (SBDL) regions on the sigma-1 receptor are likely to interact selectively with N-alkyl amines such as the endogenous sphingolipids and with synthetic N-alkylamines and N-aralkylamines derivatives. A proposed model for the sigma-1 receptor is presented.
Export Options
About this article
Cite this article as:
E. Ruoho Arnold, B. Chu Uyen, Ramachandran Subramaniam, Fontanilla Dominique, Mavlyutov Timur and R. Hajipour Abdol, The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436584
DOI https://dx.doi.org/10.2174/138161212799436584 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Imaging in Testicular Cancer
Current Medical Imaging Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Stromal Cell-Derived Factor (SDF) 2 and the Endoplasmic Reticulum Stress Response of Trophoblast Cells in Gestational Diabetes Mellitus and <i>In vitro</i> Hyperglycaemic Condition
Current Vascular Pharmacology Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science The Congenital Cytomegalovirus Infection: Virus-Host Interaction for Defense and Transmission
Current Pharmaceutical Biotechnology Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Drug Transport Across the Placenta
Current Pharmaceutical Biotechnology Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology